The professional society that writes the treatment playbook for America's hardest-to-treat bacterial infections has issued a new version, and the timing is not coincidental. The Infectious Diseases Society of America published its updated guidance on antimicrobial-resistant Gram-negative infections in Clinical Infectious Diseases, replacing earlier versions that hospitals have relied on.
The update matters because the bacteria moved first. Federal laboratory surveillance has documented a sharp rise in a resistance gene that disables not only last-resort antibiotics but also several newer drugs specifically developed to combat resistance, and clinicians have been making treatment decisions in that gap.
